Linda von Rosenvinge, IQ Practice Lead of Greater Than One, explores some of the reasons behind data mishaps and recommends remedies every healthcare marketer can incorporate into their research protocols.
California surpasses New York as U.S. state with most Covid-19 deaths
Andrew Cuomo (NY), California, Coronavirus Disease (COVID-19) Pandemic, Coronavirus immunizations, Coronavirus Infections, COVID-19 Deaths, Covid-19 Epicenter, COVID-19 Mortality, COVID-19 Vaccines, Death Tolls, Gavin Newsom (Calif.), Hospitalized COVID-19 Patients, New York, U.S. Centers for Disease Control and Prevention, United StatesCalifornia surpassed New York on Feb. 9 as the U.S. state with the most coronavirus deaths, a grim reminder of the pandemic’s toll even as the vaccine rollout and a sharp drop in new cases buoyed hopes of life eventually returning to normal.
A final analysis of the Phase III TITAN study shows that Janssen’s Erleada (apalutamide), when added to androgen deprivation therapy, significantly improved overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with placebo.
As Death Toll Climbs, WHO Finds No Benefit with 4 Top Covid-19 Treatments
Antiretrovirals, Biopharma Companies, Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, Hospitalized COVID-19 Patients, Hydroxychloroquine, Interferon-beta-1a, Lopinavir, Mortality Rates, New England Journal of Medicine, R&D, Remdesivir, World Health OrganizationOnce touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.
Convalescent Plasma Flunks Study in Covid-19 Patients with Severe Pneumonia
Argentina, Convalescent Plasma, COVID-19 Infections, Covid-19 Pneumonia, COVID-19 Studies, Emergency Use Authorization, FDA, Mortality, R&D, SARS-CoV-2 virus, The New England Journal of Medicine (NEJM), U.S. Health Secretary Alex AzarA study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.
Chicago and Detroit told to hunker down as pandemic surges
California, Chicago, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Infections, COVID-19 cases, COVID-19 Deaths, Detroit, Illinois, Iowa, Michigan, Midwest, Minnesota, Mortality Rates, Reuters Tally, United States, University of Washington's Institute for Health Metrics and Evaluation (IHME)Chicago’s mayor issued a month-long stay-at-home advisory, and Detroit’s public schools called a halt to in-person instruction to curb the spread of the coronavirus as more than a dozen U.S. states reported a doubling of new Covid-19 cases in the last two weeks.
WHO study says remdesivir did not cut hospital stay or mortality in Covid-19 patients
Antivirals, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Covid-19 Data, Hospitalized COVID-19 Patients, Hydroxychloroquine, Immunomodulator Drugs, Monoclonal Antibodies, Mortality, R&D, Remdesivir, World Health OrganizationGilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
Final data from Gilead Sciences Inc.’s antiviral drug remdesivir showed the treatment cut Covid-19 recovery time by five days compared with patients who got a placebo, one day faster than indicated in preliminary data, the company and researchers said.
After a disappointing end to a nine-year trial, the U.S. Food and Drug Administration officially gave AMAG Pharmaceuticals notice of the proposal to withdraw approval of Makena, an injectable progestin treatment to reduce preterm births.
One of medicine’s costliest treatment areas could become even more pricey as Biogen seeks to layer the company’s $750,000 spinal muscular atrophy drug on top of the $2.1 million-per-patient Novartis gene therapy Zolgensma.